Lack of bioeffects of ultrasound energy after intravenous administration of FS069 (Optison) in the anesthetized rabbit.
The current study was designed to provide a sensitive in vivo model to maximize the potential bioeffects (measured by hemolysis) of B-mode ultrasound energy in combination with FS069 (Optison). B-mode ultrasound energy was delivered to anesthetized male New Zealand white rabbits with a phased array 5 MHz transducer on a Hewlett-Packard Sonos 1500 ultrasonograph, with transmit level set to maximum (40 dB, approx 135 W/cm2). FS069 (Optison), latex particles in human albumin, or human albumin alone (vehicle) was infused via an ear vein at 0.6 mL/kg. No statistically significant changes were noted in serum free hemoglobin or lactate dehydrogenase either over time or between groups.
Killam
A L
AL
Molecular Biosystems, Inc., San Diego, California 92121, USA.
Greener
Y
Y
McFerran
B A
BA
Maniquis
J
J
Bloom
A
A
Widder
K J
KJ
Dittrich
H C
HC
D000418:Albumins / Q000008:administration & dosage*; D000768:Anesthesia, General; D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage*; D005466:Fluorocarbons / Q000008:administration & dosage*; D006461:Hemolysis; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008863:Microspheres; D011817:Rabbits; D014465:Ultrasonics / Q000009:adverse effects*; D014463:Ultrasonography / Q000009:adverse effects
D000418:Albumins; D003287:Contrast Media; C099458:FS 069; D005466:Fluorocarbons